Comparison
While Sermorelin is used as a diagnostic agent for assessing GH secretory capacity and as a research tool or off-label therapy to increase endogenous GH in GH-deficient or age-related contexts1727, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While Sermorelin works as a synthetic 29-amino-acid peptide identical to the 1–29 N-terminal fragment of human GHRH that stimulates GH synthesis and secretion by binding pituitary GHRH receptors1727120, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
Sermorelin is 29 amino acids long, whereas Tirzepatide is longer as it has a length of 39 amino acids. Sermorelin is made up of a sequence of Tyrosine, Alanine, Aspartic acid, Alanine, Isoleucine, Phenylalanine, Threonine, Asparagine, Serine, Tyrosine, Arginine, Lysine, Valine, Leucine, Glycine, Glutamine, Leucine, Serine, Alanine, Arginine, Lysine, Leucine, Leucine, Glutamine, Aspartic acid, Isoleucine, Methionine, Serine, Arginine. Tirzepatide is made up of a sequence of sequence data not available in the current dataset.
Sermorelin
GHRH
Tirzepatide
Not assigned in the current dataset.